戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 arly as 24 h after the administration of the radioimmunoconjugate.
2 oinjection of 0.1 mg of panitumumab with the radioimmunoconjugate.
3 ted a high HER1-specific tumor uptake of the radioimmunoconjugate.
4 imab was developed and used as a nonspecific radioimmunoconjugate.
5 cularly defined antibody-drug conjugates and radioimmunoconjugates.
6 have demonstrated the safety and efficacy of radioimmunoconjugates.
7 clonal anti-CD20 has impressive activity and radioimmunoconjugates.
8 e after 15 h ranged from 50% to 75% for both radioimmunoconjugates.
9 d warrant the clinical development of N4MU01 radioimmunoconjugates.
10  healthy organs compared to directly labeled radioimmunoconjugates.
11 pes that can be targeted with antibody-based radioimmunoconjugates.
12 nd prostate cancer patients who received the radioimmunoconjugate 111In-2IT-BAD-m170, 91% and 94% of
13   The next-generation beta-particle-emitting radioimmunoconjugate (177)Lu-lilotomab-satetraxetan (Bet
14                                          The radioimmunoconjugate, 67Cu-21T-BAT-Lym-1, has been shown
15 T imaging using the nonoverlapping anti-EGFR radioimmunoconjugate [89Zr]Zr-DFO-matuzumab before and a
16                       The approved anti-CD20 radioimmunoconjugates ((90)Y-ibritumomab tiuxetan or (13
17                                    The novel radioimmunoconjugate, 90Y-DOTA-peptide-chimeric L6 (ChL6
18 mg dependent on the specific activity of the radioimmunoconjugate and was infused at a rate of 0.5-1
19  conjugates, small-molecule drug conjugates, radioimmunoconjugates and, more recently, chimeric antig
20  purging mechanisms and nonmyeloablative and radioimmunoconjugated antibodies as alternate preparativ
21                                              Radioimmunoconjugates are associated with transient panc
22                       Thereby, corresponding radioimmunoconjugates are formed in vivo and, consequent
23      This article reviews the development of radioimmunoconjugates as a new class of cancer therapeut
24 aims to potentiate the therapeutic action of radioimmunoconjugates at the tumor site and thus improve
25 conjugated anti-CD20 antibody therapy with a radioimmunoconjugate binding to a noncompeting antigen m
26 We have developed (111)In-labeled bispecific radioimmunoconjugates (bsRICs) that bind HER2 and EGFR o
27    Our objective was to construct bispecific radioimmunoconjugates (bsRICs) that recognize HER2 and H
28 ng agents allow formation of stable metallic radioimmunoconjugates but have been reported to be immun
29 cause of this uptake is the sequestration of radioimmunoconjugates by immune cells bearing Fc-gamma-r
30 ncer, but the protracted circulation time of radioimmunoconjugates can lead to high radiation doses t
31                        In vivo evaluation of radioimmunoconjugates confirmed the prolonged stability
32 -pertuzumab PET, a site-specifically labeled radioimmunoconjugate designed to circumvent the limitati
33  cancer xenografts and compared to analogous radioimmunoconjugates employing the ubiquitous chelator
34                  (177)Lu-RS7 is an effective radioimmunoconjugate for radioimmunotherapy.
35 ane-N,N',N",N"'-tetraacetic acid) is a novel radioimmunoconjugate for targeting radiation to cancer.
36 k demonstrates it is practical to use (67)Cu radioimmunoconjugates for cancer radioimmunotheranostics
37 Drug Administration will approve one or more radioimmunoconjugates for clinical use.
38 been recently investigated for the design of radioimmunoconjugates for immuno-PET.
39 ntial for use in the design and synthesis of radioimmunoconjugates for immunoPET.
40 isting immunotherapies such as rituximab and radioimmunoconjugates has generated much data in the pas
41 sed bispecific antibodies, immunotoxins, and radioimmunoconjugates have been examined in preclinical
42                                     Metallic radioimmunoconjugates have promise for radioimmunoimagin
43 t uptake of the corresponding (89)Zr-labeled radioimmunoconjugates (i.e., liver activity concentratio
44                                          Two radioimmunoconjugates, ibritumomab tiuxetan (Zevalin) an
45 ts, with trials now seeking to incorporate a radioimmunoconjugate in various settings.
46 tic acid binds 67Cu tightly to form a stable radioimmunoconjugate in vivo.
47 nti-epithelial glycoprotein-1 MAb) furnished radioimmunoconjugates in good overall incorporations, wi
48                  However, the high uptake of radioimmunoconjugates in nontarget tissues such as the l
49 r overall cellular binding of the PEG(6)-DM1 radioimmunoconjugates, internalization was higher for PE
50 el of ovarian carcinoma after injection of a radioimmunoconjugate labeled with (211)At for TAT.
51 ical limitations of intranuclear SPECT using radioimmunoconjugates, notably the lower target-abundanc
52 ntibody engineering has been used to improve radioimmunoconjugates on four fronts: optimizing pharmac
53 ed with increased effective half-life of the radioimmunoconjugate (P = .009).
54                   As opposed to conventional radioimmunoconjugates, pretargeted approaches separate t
55 )Lu or (161)Tb and purification, we assessed radioimmunoconjugate quality by determining the radioche
56 effector type: immunotoxins (protein toxin), radioimmunoconjugates (radionuclide), and antibody drug
57              Progress in the clinical use of radioimmunoconjugates remains hindered by complexity of
58 ive monoclonal antibodies, immunotoxins, and radioimmunoconjugates (RICs) has stimulated considerable
59 kinetic profile of the [(89)Zr]Zr-DFO-N4MU01 radioimmunoconjugate showed biphasic distribution with a
60                              Tumor-selective radioimmunoconjugates specific for embryonal tumors of c
61                                         Both radioimmunoconjugates specifically bound to HCT-15 cells
62                                              Radioimmunoconjugates targeting GD2 may have clinical ut
63                                              Radioimmunoconjugates targeting human epidermal growth f
64                           Interestingly, the radioimmunoconjugate that yielded the best tumor-to-norm
65  together, our findings establish the use of radioimmunoconjugates that target gammaH2AX as a noninva
66 or molecules are delivered as presynthesised radioimmunoconjugates, the pretargeting approach is a mu
67 jection of (111)In-hu3S193 and (86)Y-hu3S193 radioimmunoconjugates, the uptake of (111)In and (86)Y a
68 n anti-CD20 therapy enhances the efficacy of radioimmunoconjugate therapy.
69 hether to incorporate monoclonal antibody or radioimmunoconjugate therapy.
70 I as an adjunct to determine localization of radioimmunoconjugates to hematolymphoid tissues.
71 raise important questions concerning current radioimmunoconjugate treatment regimens and ways to impr
72 be given to fractionating or giving multiple radioimmunoconjugate treatments.
73 tivity concentrations of the glycoengineered radioimmunoconjugates, ultimately yielding improved tumo
74 ere analyzed for retention and metabolism of radioimmunoconjugates using cellular-radioimmunoassays,
75                                          The radioimmunoconjugate was able to detect known sites of m
76  of the [(89)Zr]Zr-deferoxamine (DFO)-N4MU01 radioimmunoconjugate was studied in mice bearing nectin-
77  reaction assays, and blood clearance of the radioimmunoconjugate was studied using enzyme-linked imm
78                                          The radioimmunoconjugate was tested for immunoreactivity, in
79        The in vivo behavior of the resulting radioimmunoconjugates was investigated in mice bearing o
80        High uptake and good retention of the radioimmunoconjugate were observed at the surface of tum
81                   In this study, theranostic radioimmunoconjugates were developed using a fully human
82 perties and therapeutic effectiveness of the radioimmunoconjugates were evaluated using TNBC models.
83                                              Radioimmunoconjugates were retained in the peritoneal ca
84 n, dosimetry, and therapeutic effect of both radioimmunoconjugates were studied in a xenograft mouse
85 standing the unique properties of this novel radioimmunoconjugate will facilitate its safe and effect
86 25)Ac, high technical requirement to prepare radioimmunoconjugate with very short half-life (T(1/2) =
87 Fc domain, we set out to investigate whether radioimmunoconjugates with truncated glycans would exhib